臨床試驗

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT：NCT05934526 · COMPLETED

NCT IDNCT05934526

狀態COMPLETED

開始日期2023-12-28

完成時間2025-12-22

SponsorGB002, Inc. (INDUSTRY)

First posted2023-07-07

Last updated2026-05-19

簡要摘要

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。